San Francisco – do you want to know the difference between Non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma? Do you want to know what my top 10 abstracts are in Hodgkin’s Lymphoma and aggressive lymphomas that discuss promising new agents in development? Which of these abstracts should have been a plenary at the meeting?

If the answer is “Yes” to the above, then this blog post is for you!

When I consider what is worthy of a plenary presentation at a meeting like ASH, I think back to the Gleevec phase 1 data presented at ASH in 1999 when I was in Novartis Oncology New Products. It’s data that makes you go WOW!, is transformative or has the potential to change the field. That’s what Gleevec did in CML.

To read the full article, you can log-in to learn more:

This content is restricted to subscribers

Posted by